Additional heterologous versus homologous booster vaccination in immunosuppressed patients without SARS-CoV-2 antibody seroconversion after primary mRNA vaccination: a randomized controlled trial
Michael Bonelli, View ORCID ProfileDaniel Mrak, Selma Tobudic, Daniela Sieghart, Maximilian Koblischke, Peter Mandl, Barbara Kornek, Elisabeth Simader, Helga Radner, Thomas Perkmann, View ORCID ProfileHelmuth Haslacher, Margareta Mayer, Philipp Hofer, Kurt Redlich, Emma Husar-Memmer, Ruth Fritsch-Stork, Renate Thalhammer, Karin Stiasny, Stefan Winkler, Josef S. Smolen, Judith H. Aberle, Markus Zeitlinger, Leonhard X. Heinz, Daniel Aletaha
doi: https://doi.org/10.1101/2021.09.05.21263125
Michael Bonelli
1Division of Rheumatology, Department of Internal Medicine III, Medical University of Vienna, Austria
Daniel Mrak
1Division of Rheumatology, Department of Internal Medicine III, Medical University of Vienna, Austria
Selma Tobudic
2Division of Infectious Diseases and Tropical Medicine, Department of Internal Medicine I, Medical University of Vienna, Austria
Daniela Sieghart
1Division of Rheumatology, Department of Internal Medicine III, Medical University of Vienna, Austria
Maximilian Koblischke
3Center for Virology, Medical University of Vienna, Austria
Peter Mandl
1Division of Rheumatology, Department of Internal Medicine III, Medical University of Vienna, Austria
Barbara Kornek
4Department of Neurology, Medical University of Vienna, Austria
Elisabeth Simader
1Division of Rheumatology, Department of Internal Medicine III, Medical University of Vienna, Austria
Helga Radner
1Division of Rheumatology, Department of Internal Medicine III, Medical University of Vienna, Austria
Thomas Perkmann
5Department of Laboratory Medicine, Medical University of Vienna, Austria
Helmuth Haslacher
5Department of Laboratory Medicine, Medical University of Vienna, Austria
Margareta Mayer
3Center for Virology, Medical University of Vienna, Austria
Philipp Hofer
6Department of Pathology, Medical University of Vienna, Vienna, Austria
Kurt Redlich
7nd, Vienna, Austria
Emma Husar-Memmer
8School of Medicine, Sigmund Freud University Vienna, Vienna, Austria; st, Vienna, Austria; Ludwig Boltzmann Institute of Osteology, Hanusch Hospital and AUVA Trauma Center Meidling, Vienna, Austria
Ruth Fritsch-Stork
8School of Medicine, Sigmund Freud University Vienna, Vienna, Austria; st, Vienna, Austria; Ludwig Boltzmann Institute of Osteology, Hanusch Hospital and AUVA Trauma Center Meidling, Vienna, Austria
Renate Thalhammer
5Department of Laboratory Medicine, Medical University of Vienna, Austria
Karin Stiasny
3Center for Virology, Medical University of Vienna, Austria
Stefan Winkler
2Division of Infectious Diseases and Tropical Medicine, Department of Internal Medicine I, Medical University of Vienna, Austria
Josef S. Smolen
1Division of Rheumatology, Department of Internal Medicine III, Medical University of Vienna, Austria
Judith H. Aberle
3Center for Virology, Medical University of Vienna, Austria
Markus Zeitlinger
9Departement of Clinical Pharmacology, Medical University of Vienna, Austria
Leonhard X. Heinz
1Division of Rheumatology, Department of Internal Medicine III, Medical University of Vienna, Austria
Daniel Aletaha
1Division of Rheumatology, Department of Internal Medicine III, Medical University of Vienna, Austria

- Supplementary material[supplements/263125_file02.docx]
Posted September 08, 2021.
Additional heterologous versus homologous booster vaccination in immunosuppressed patients without SARS-CoV-2 antibody seroconversion after primary mRNA vaccination: a randomized controlled trial
Michael Bonelli, Daniel Mrak, Selma Tobudic, Daniela Sieghart, Maximilian Koblischke, Peter Mandl, Barbara Kornek, Elisabeth Simader, Helga Radner, Thomas Perkmann, Helmuth Haslacher, Margareta Mayer, Philipp Hofer, Kurt Redlich, Emma Husar-Memmer, Ruth Fritsch-Stork, Renate Thalhammer, Karin Stiasny, Stefan Winkler, Josef S. Smolen, Judith H. Aberle, Markus Zeitlinger, Leonhard X. Heinz, Daniel Aletaha
medRxiv 2021.09.05.21263125; doi: https://doi.org/10.1101/2021.09.05.21263125
Additional heterologous versus homologous booster vaccination in immunosuppressed patients without SARS-CoV-2 antibody seroconversion after primary mRNA vaccination: a randomized controlled trial
Michael Bonelli, Daniel Mrak, Selma Tobudic, Daniela Sieghart, Maximilian Koblischke, Peter Mandl, Barbara Kornek, Elisabeth Simader, Helga Radner, Thomas Perkmann, Helmuth Haslacher, Margareta Mayer, Philipp Hofer, Kurt Redlich, Emma Husar-Memmer, Ruth Fritsch-Stork, Renate Thalhammer, Karin Stiasny, Stefan Winkler, Josef S. Smolen, Judith H. Aberle, Markus Zeitlinger, Leonhard X. Heinz, Daniel Aletaha
medRxiv 2021.09.05.21263125; doi: https://doi.org/10.1101/2021.09.05.21263125
Subject Area
Subject Areas
- Addiction Medicine (413)
- Allergy and Immunology (727)
- Anesthesia (215)
- Cardiovascular Medicine (3126)
- Dermatology (265)
- Emergency Medicine (464)
- Epidemiology (13075)
- Forensic Medicine (14)
- Gastroenterology (868)
- Genetic and Genomic Medicine (4893)
- Geriatric Medicine (451)
- Health Economics (755)
- Health Informatics (3086)
- Health Policy (1109)
- Hematology (411)
- HIV/AIDS (973)
- Medical Education (457)
- Medical Ethics (121)
- Nephrology (502)
- Neurology (4664)
- Nursing (248)
- Nutrition (691)
- Oncology (2405)
- Ophthalmology (683)
- Orthopedics (270)
- Otolaryngology (333)
- Pain Medicine (311)
- Palliative Medicine (88)
- Pathology (519)
- Pediatrics (1249)
- Primary Care Research (526)
- Public and Global Health (7231)
- Radiology and Imaging (1613)
- Respiratory Medicine (945)
- Rheumatology (462)
- Sports Medicine (403)
- Surgery (518)
- Toxicology (65)
- Transplantation (222)
- Urology (192)